A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Carcinosarcoma
  • Mixed Tumor, Mullerian
  • Neoplasm Recurrence, Local
  • Pyrimidines
  • Receptors, Vascular Endothelial Growth Factor
  • Sulfonamides
  • Uterine Neoplasms

abstract

  • Pazopanib demonstrated minimal activity as a second or third line treatment for advanced uterine carcinosarcoma. Potential clinical trial participation should be discussed with the patients.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4360988

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2014.02.036

PubMed ID

  • 24594074

Additional Document Info

start page

  • 537

end page

  • 41

volume

  • 133

number

  • 3